We use cookies to improve your experience. By your continued use of this site you accept such use.
MSD

  • Multimedia content

  • Images (2)
    • Dr. Sabrina Kitaka, Senior Lecturer at Makerere University
    • Prof. Hannelie Meyer, Head of the South African Vaccination and Immunisation Centre
  • All (2)
Source: MSD |

Human Papillomavirus (HPV) vaccination in Africa: Urgent steps needed to address low uptake amid rising hesitancy

The World Health Organization (WHO) estimates that 94% of global cervical cancer deaths occur in low- and middle-income countries, with sub-Saharan Africa heavily affected

HPV is fuelling high cervical cancer rates in sub-Saharan Africa despite the availability of effective vaccines. Yet uptake remains low, driven largely by vaccine hesitancy. In South Africa alone, most participants (71%) were hesitant to receive at least one of the vacines in the country, according to the Vaccine Confidence…

MSD

  • Multimedia content

  • Images (1)
    • Mme Bineta Diop - African Union Special Envoy on Women Peace and Security
  • All (1)
Source: MSD |

The pandemic has reversed decades of progress in closing the gender divide (By Mme Bineta Diop)

Women have borne the brunt of the pandemic and the economic downturn caused by the spread of the virus and measures to combat it

By Mme Bineta Diop, African Union Special Envoy on Women Peace and Security With the COVID-19 pandemic still raging across the world, a few affluent nations have got transmission under control, and we are beginning to dream of better days. However economic recovery will be pointless, if it does not…

MSD
Source: MSD |

Expansion of Elkton, Virginia Manufacturing Facility to Further Increase MSD’s HPV Vaccine Supply and Support Broader and Equitable Access

Supply Increase to Help Meet Growing Global Demand

MSD (NYSE: MRK) (www.MSD.com), a trade name of Merck & Co., Inc, Kenilworth, NJ, USA, reaffirmed its commitment to enable broad equitable access to the company’s HPV vaccines. To support this, the company has invested significantly in manufacturing, and recently expanded its vaccines manufacturing facility located in Elkton, VA, completing…

MSD
Source: MSD |

Global pharma firm appoints South African MD to lead sub-Saharan Africa operations

Mr Bashman will succeed Dr Priya Agrawal, who has been appointed chief behavioural science officer in global vaccines in the international operations of the company

International healthcare and pharmaceuticals group MSD (www.MSD.co.za) has appointed Zwelethu Bashman to be the next managing director of its operations in South Africa and Sub-Saharan Africa. Mr Bashman will succeed Dr Priya Agrawal, who has been appointed chief behavioural science officer in global vaccines in the international operations of the company.…

MSD
Source: MSD |

Webinar: Vaccination in Africa - A Public Health Priority

The webinar will be a platform to educate and inform journalists on the importance of vaccination and on concepts related to immunisation in sub-Saharan Africa

Global NGO Amref Health Africa (https://Amref.org/home/), biopharmaceutical company MSD (www.MSD.com) and the Africa Centres for Disease Control and Prevention (Africa CDC) (https://AfricaCDC.org) will hold a webinar for journalists to discuss the importance of vaccination, and the media’s central role in creating awareness of the value of immunization as a public…

MSD
Source: MSD |

Cote d’ Ivoire and Liberia both Launch National Immunisation Programmes for Human-Papillomavirus (HPV)

Cervical cancer is the second most common cancer among women aged 15 to 44 years in Cote D’ Ivoire

MSD (www.MSD.co.za), known as Merck & Co., Inc., (NYSE: MRK) in the United States and Canada, congratulates both Cote d’ Ivoire and Liberia on the successful launch of the National Immunisation Programme (NIP) for the Human-Papillomavirus (HPV - the main cause of cervical cancer).[1] Approximately 530 000 women are diagnosed…

MSD
Source: MSD |

ERVEBO® [Ebola Zaire Vaccine] Awarded Prequalification Status by the World Health Organization (WHO)

WHO prequalification means that ERVEBO has met the WHO’s standards of quality, efficacy and tolerability

Merck (NYSE: MRK), known as MSD (www.MSD.com) outside the United States and Canada, today announced that ERVEBO [Ebola Zaire Vaccine (rVSVΔ-ZEBOV-GP live)] has been awarded prequalification status by the World Health Organization (WHO).  ERVEBO is the first vaccine to be prequalified by the WHO for the prevention of Ebola Virus…

MSD
Source: MSD |

Kenya Launches National Immunisation Programme for Human-Papillomavirus (HPV)

The launch of the HPV program in Kenya is a watershed moment for the country

MSD (www.MSD.co.za), known as Merck & Co., Inc., (NYSE: MRK) in the United States and Canada, congratulates Kenya on the successful launch of the National Immunisation Programme (NIP) for the Human-Papillomavirus (HPV - the main cause of cervical cancer). [1] Approximately 530 000 women are diagnosed with cervical cancer around…

MSD
Source: MSD |

Dr Priya Agrawal appointed Managing Director for MSD - South Africa and Sub-Saharan Africa Cluster

Dr Agrawal brings a wealth of public health experience with a strong track record for advancing successful public health initiatives within both the private and public sectors

MSD (www.MSD.co.za), known as Merck & Co., Inc., in the United States and Canada is pleased to announce the appointment of Dr Priya Agrawal as Managing Director for the South Africa and Sub-Saharan Africa Cluster. Dr Agrawal trained as an Obstetrician and Gynaecologist in the United Kingdom. After receiving her…

MSD
Source: MSD |

The Foundation of Merck & Co., Inc., Kenilworth, NJ, USA Announces Grant to American Cancer Society to Improve Access to Cancer Care in Resource-Limited Settings

$1.99 Million Grant Supports Patient Navigation Initiative in East Africa

The Foundation of Merck & Co., Inc., Kenilworth, NJ, USA (the Foundation) and the American Cancer Society (ACS) announced today that the Foundation awarded a $1.99 million, five-year grant to ACS to improve support and access to care for people living with cancer in low-and-middle-income countries, particularly in East Africa. This…